UNASSIGNED:在亚洲国家的真实世界研究中评估玻璃体内注射抗血管内皮生长因子(抗VEGF)治疗糖尿病性黄斑水肿(DME)的视觉结果和安全性。
UNASSIGNED:对电子文献数据库的系统回顾(Embase,Medline,从2010年1月1日至2021年3月16日,在Cochrane图书馆进行),以确定观察性研究,这些研究报告了亚洲DME抗VEGF治疗的临床和安全性结果。我们分析了基线患者特征,治疗模式,平均注射次数,最佳矫正视力(BCVA),视网膜厚度,和安全结果。
UNASSIGNED:本综述包括71项研究。大多数研究报道了雷珠单抗治疗DME(n=33),其次是aflibercept(n=13),贝伐单抗(n=28),和conbercept(n=9)。12个月时,雷珠单抗的累积平均注射次数,aflibercept,conbercept分别为5.2、4.6和6。在12个月的随访中,累积平均BCVA增益为6.8个字母(雷珠单抗),4.6字母(aflibercept),4.9个字母(贝伐单抗),和8.3个字母(conbercept)。12个月时视网膜厚度的累积平均减少为116.9μm(雷珠单抗),105.9μm(阿柏西普),81.7μm(贝伐单抗),和135.2μm(conbercept)。在12个月时,平均注射次数与BCVA变化之间观察到了很强的正相关(r=0.78)。在12个月时,平均注射次数和平均视网膜厚度减少之间观察到中度正相关(r=0.54)。在12个月时,基线视网膜厚度与视力之间观察到弱正相关。基线BCVA和平均注射次数是12个月时BCVA的预测因子。
UNASSIGNED:所有抗VEGF在亚洲DME治疗中均有效。数据表明,在1年的随访中,更多的抗VEGF注射与BCVA的更好改善和视网膜厚度的适度减少有关。
UNASSIGNED: To evaluate the visual outcomes and safety profile of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the treatment of diabetic macular edema (
DME) in real-world studies in Asian countries.
UNASSIGNED: A systematic
review of electronic literature databases (Embase, Medline, and the Cochrane Library from January 1, 2010, to March 16, 2021) was conducted to identify observational studies that reported clinical and safety outcomes of anti-VEGF treatments for
DME in Asia. We analyzed baseline patient characteristics, treatment patterns, mean number of injections, best-corrected visual acuity (BCVA), retinal thickness, and safety outcomes.
UNASSIGNED: Seventy-one studies were included in this
review. Most studies reported treatment of DME with ranibizumab (n = 33), followed by aflibercept (n = 13), bevacizumab (n = 28), and conbercept (n = 9). At 12 months, the cumulative mean number of injections for ranibizumab, aflibercept, and conbercept was 5.2, 4.6, and 6, respectively. At the 12-month follow-up, the cumulative mean BCVA gain was 6.8 letters (ranibizumab), 4.6 letters (aflibercept), 4.9 letters (bevacizumab), and 8.3 letters (conbercept). The cumulative mean reduction in retinal thickness at 12 months was 116.9 μm (ranibizumab), 105.9 μm (aflibercept), 81.7 μm (bevacizumab), and 135.2 μm (conbercept). A strong positive correlation (r = 0.78) was observed between mean number of injections and change in BCVA at 12 months. A moderate positive correlation (r = 0.54) was observed between mean number of injections and mean reduction in retinal thickness at 12 months. A weak positive correlation was observed between baseline retinal thickness and visual acuity at 12 months. Baseline BCVA and mean number of injections were predictors of BCVA at 12 months.
UNASSIGNED: All anti-VEGFs were effective in the treatment of
DME in Asia. The data suggest that a greater number of anti-VEGF injections was associated with better improvement in BCVA and moderate reduction in retinal thickness at the 1-year follow-up.